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Abstract
Human Immunodeficiency Viruses are a group of lentiviruses that have seen a lot of
study ever since their discovery. HIV-1, the most common and virulent form of the virus, has
proven to be quite deadly when untreated, so any research into the mechanisms of HIV
pathogenesis and replication could have major medical applications all over the world. HIV-1 is
a sexually transmitted virus that compromises the hosts immune system and eventually leads to
the patient developing AIDS, a life-threatening condition that nearly half of people infected with
HIV will develop within ten years.
Our study sets out to determine exactly how HIV-1 is able to facilitate its own spread
through the use of its viral proteins and genome. The protein we focus on in this study is the Tat
protein. Tat is short for Trans-Activator of Transcription. It gets this name from the role that the
protein plays in the facilitation of the transcription of the viral genome once it invades a host cell.
It performs this role by binding to the RNA stem-loop structure known as TAR located at the 5’
end of HIV-1 transcripts. Once bound, Tat assists in recruiting additional transcriptional
elements, increasing the transcription of viral RNA. We seek to determine whether the presence
of tat also influences the mechanisms of blood coagulation in the body such as the contact
activation pathway and the kallikrein-kinin system, due to the high amount of cardiovascular
ailments that are often associated with HIV.
`

We decided to conduct a time course using the plasma of HIV-1 transgenic mice to see if

the presence of Tat protein in the plasma would affect the production of kallikrein and its other
downstream products in the kallikrein kinin system. One of these byproducts, bradykinin, has
also been implicated in altering endothelial structure and the compromise of vascular selectivity
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and permeability. This alteration in selectivity associated with bradykinin may play a role in
allowing HIV virus particles to more easily spread to other cells and also to cross the blood brain
barrier, compromising the brain to HIV infection.
The results of the study showed that the presence of Tat is indeed associated with higher
levels of kallikrein activity in the plasma compared to when Tat is absent. We also found that
Tat+ plasma contains a higher level of kallikrein itself, indicating that the byproduct, bradykinin,
is also being produced at a higher level. These higher levels of kallikrein activity and increase in
kallikrein production, signal that the presence of Tat protein is leading to higher rates of reaction
in the kallikrein-kinin system, indirectly resulting in the production of excess bradykinin and also
the compromise of endothelial cells.

v

Table of Contents
List of Diagrams and Figures ……………………………………………………………vii
1. Introduction ………………………………………………………………………...1
a. Human Immunodeficiency Virus ………………………………………. 1
b. Tat Protein ………………………………………………………………. 4
c. Contact Activation Pathway ……………………………………………. 4
i. Factor XII ………………………………………………………… 5
ii. Factor XI …………………………………………………………..6
iii. Prekallikrein ……………………………………………………….8
iv. High Molecular Weight Kininogen ………………………………..8
v. Bradykinin …………………………………………………………9
2. Goals and Objectives ……………………………………………………………….11
3. Methods and Materials ……………………………………………………………..12
a. S2302 ……………………………………………………………………….12
b. Time Course ……………………………………………………………….13
c. Plasma Samples ……………………………………………………………15
d. Inhibition Study ……………………………………………………………16
4. Data and Results ……………………………………………………………………..16
a. Time Course Data ………………………………………………………….17
b. Inhibition Data ……………………………………………………………..21
5. Conclusion ……………………………………………………………………………22
6. Bibliography ………………………………………………………………………….24

vi

List of Diagrams and Figures
-

Figure 1

HIV Genome ………………………………………………………3

-

Figure 2

Kallikrein-Kinin System……………………………………………5

-

Figure 3

Cleavage of HK by Kallikrein……………………………………...9

-

Figure 4

Physiological Effects of Bradykinin……………………………….10

-

Figure 5

Example of Microplate Setup Used………………………………..14

-

Figure 6

Kinetics of Experiment 1…………………………………………..17

-

Figure 7

Kinetics of Experiment 2…………………………………………...17

-

Figure 8

Kinetics of Experiment 3…………………………………………..18

-

Figure 9

Kinetics of Experiment 4…………………………………………..18

-

Figure 10

Kinetics of Experiment 5…………………………………………..19

-

Figure 11

Relative Rates of Substrate Cleavage………………………………20

-

Figure 12

Kallikrein Activity in the Plasma…………………………………..20

-

Figure 13

Inhibition of Kallikrein by Kallistop and SBTI……………………21

vii

Introduction
Human Immunodeficiency Virus
Human immunodeficiency viruses are a group of viruses belonging to the species
Lentivirus (a subgroup of retrovirus) that infect humans. HIV is mainly spread through sexual
contact or during an exchange of bodily fluids such as a blood transfusion. Mothers infected with
HIV are also capable of spreading the virus non-sexually to their infants during pregnancy,
childbirth, and through breastfeeding. This is due to the fact that HIV stays present as free virus
particles within these bodily fluids and also as virus within infected immune cells8. Therefore,
the exchange of these fluids can result in a new infection. If HIV infection is not treated properly
and is able to progress, the patient will eventually develop acquired immunodeficiency syndrome
(AIDS). Patients suffering from AIDS will be at a significantly larger risk of developing lifethreatening infections and will be much more susceptible to the development of cancer. There
are two different species of HIV: HIV-1 and HIV-2, each of which have their own unique
characteristics. HIV-1 is the far more prevalent species, responsible for the vast majority of cases
of the virus and is believed to be significantly more virulent and has a much higher infectivity7.
HIV-2, on the other hand, has a lower virulence and infectivity, and because of this, is rarely
seen outside of West Africa. The transgenic mice used in this experiment have been infected
with HIV-1 so we will be focusing on this specific species of the virus in the rest of the paper.
While the relation between HIV and bleeding disorders has not been researched
thoroughly, studies have shown that HIV infection is associated with serious cardiovascular
abnormalities. Post-mortem examinations of children and young-patients who had died from
AIDS reveal a litany of pathologies including, vascular wall infiltration by mononuclear cells
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and lymphocytes, advanced atherosclerotic lesions, and medium to large-artery aneurysms21.
Another study also showed that HIV-1 infected children, when compared to healthy children,
show increased stiffness of arterial walls along with impaired endothelial function measured by
fibromuscular dysplasia and reduced distensibility of the carotids21.
HIV shows both similar and different characteristics in relation to other lentiviruses. Like
other lentiviruses, HIV is transmitted as a single-stranded, positive sense, RNA virus. This RNA
is responsible for coding the genes necessary for viral function, and thus is protected by a conical
capsid consisting of 2,000 copies of the viral protein p249. The RNA is tightly bound to
nucleocapsid proteins, p7, and other enzymes, such as reverse transcriptase, proteases,
ribonuclease, and integrase, each of which is vital for the development of the virion9. This is, in
turn, surrounded by a matrix composed of the viral protein p17, which covers the capsid and
provides further protection for the virion particle. On top of this, the matrix is also surrounded by
a viral envelope characteristic of other lentiviruses. The envelope is created by taking the lipid
bilayer from the membrane of a human host cell and integrating it with the newly formed virus
particle as it buds from the cell. As a result, the envelope contains relatively few copies of HIV
envelope protein, which is made of a cap of three molecules known as glycoprotein (gp) 120 and
a stem of three gp41 molecules that provide structural support and anchor the cap into the viral
envelope9. This envelope protein is encoded by the HIV env gene, which gives the virus the
ability to attach to host cells and allows for the fusion of the viral envelope to the host’s cell
membrane, consequently resulting in the release of the viral contents of the infected cell10.
The RNA genome of HIV-1 consists of seven structural landmarks and nine genes. The
landmarks are various sequences of nucleotides that are responsible for different functions such
as binding and transcription. These landmarks are as follows: LTR, TAR, RRE, PE, SLIP, CRS,
2

and INS. The genes present in HIV (See figure 1) are gag, pol, env, tat, rev, nef, vif, vpr, vpu,
and sometimes tev (a combination of tat, env, and rev). Gag, pol, and env are the genes
containing the necessary information for the production of the structural proteins to be used in
new virus particles9. The remaining genes, tat, rev, nef, vif, vpr, and vpu, are all responsible for
regulatory function and code for proteins that control the ability of HIV to infect host cells,
undergo replication, or cause disease9. The tat gene in particular is vital for replication as it codes
for Tat proteins that drastically enhance viral transcription.

Figure 1: Structure of the HIV-1 genome. It is roughly 10,000 base pairs long and consists
of nine genes. The tat gene can be seen alongside the other regulatory genes responsible for
replication and infection.
Credit: Thomas Splettstoesser (www.scistyle.com)

Tat Protein
A Tat protein is a regulatory protein that has been encoded for by the tat gene in HIV-1.
Tat is an acronym that stands for “trans-activator of transcription”. This name is derived from its
function which is to provide a means for efficient transcription of the viral genome12. Tat does
this by binding to the RNA stem-loop structure, TAR (trans-activating response element), which
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is located on the 5’ ends of HIV-1 transcripts. Once bound to TAR, Tat is able to alter the
properties of the transcription complex and is able to recruit the positive transcription elongation
complex (P-T EFb) of CDK9 and cyclin T1, resulting in the increased production of full-length
viral RNA11.
Tat also contains a transduction domain, also known as a cell-penetrating peptide. Similar
to a Trojan horse, this domain gives Tat the ability to enter host cells by way of the cell
membrane. This is significant as a major obstacle to neural therapies has been figuring out a way
to deliver medication or certain molecules across cellular membranes and the blood/brain
barrier13. For many potential pharmaceuticals, such as neurotrophins, the endothelial wall of the
BBB is not entirely permeable, therefore any mechanism that demonstrates an ability to cross
this barrier shows great potential for medical use. It is hypothesized that some HIV virions may
gain access to the CNS through this blood/brain barrier paracellularly, aided by breaches in BBB
integrity. This is supported by early post-mortem analyses of brains infected with HIV that show
high levels of serum proteins, suggesting the degradation of the BBB has taken place.

Contact Activation Pathway
The contact activation pathway is a group of proteins in the plasma that play a role in
surface-activated blood coagulation tests. These proteins are Factor XII, prekallikrein (PK), and
High-Molecular Weight Kininogen (HK). Factor XII and PK are proteases while HK is a nonenzymatic co-factor. The contact activation pathway is initiated by the binding of Factor XII to a
negatively charged surface and the reciprocal activation of Factor XII and PK into Factor XIIa
and PKa respectively14.
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Figure 2: Kallikrein-Kinin System.
Michał B. Ponczek, Aleksandr Shamanaev, Alec LaPlace, S. Kent
Dickeson, Priyanka Srivastava, Mao-fu Sun, Andras Gruber, Christian
Kastrup, Jonas Emsley, David Gailani; The evolution of factor XI and
the kallikrein-kinin system. Blood Adv 2020; 4 (24): 6135–6147.

doi: https://doi.org/10.1182/bloodadvances.2020002456

- Factor XII and PK undergo reciprocal activation to
produce Factor XIIa and PKa. PKa then goes on to cleave
HK, releasing Bradykinin (BK) and HKa.

Factor XIIa can then go on to initiate the coagulation cascade by activating Factor XI into Factor
XIa, leading to the formation of blood clots2. The contact activation pathway can also activate
the kallikrein-kinin system in which PKa can cleave HK to form HKa, releasing a peptide known
as bradykinin (BK). Bradykinin is a molecule that plays an important role in the mediation of
inflammation and vascular permeability3.

Factor XII
Also known as Hageman Factor, human coagulation factor XII is the zymogen form of a
protein found in the plasma that plays a role in the coagulation cascade responsible for blood
clotting and hemostasis15. It was first discovered in 1955 when the blood sample of 37-year-old
John Hageman was found by doctors to have large delays to clotting times in test tubes. This was
novel, as the patient was experiencing no hemorrhagic symptoms and led the doctors to
determine that this novelty was due to the lack of an unidentified blood clotting factor. This
blood clotting factor turned out to be factor XII. The main role of factor XII in the coagulation
cascade is to be the starting point of the intrinsic pathway and to activate other coagulation
5

enzymes such as factor XI and prekallikrein in vitro. Factor XII is thought to play a smaller role
in coagulation in vivo, as patients with factor XII deficiencies do not typically experience
excessive bleeding symptoms.
As stated earlier, Factor XII is a zymogen and must be activated in order for it to fulfill
its enzymatic function. In vitro, Factor XII is activated by negatively charged surfaces such as
glass. This is makes it a very good molecule for the initiation of coagulation cascades in
laboratory studies2. In vivo, Factor XII can be activated by a number of different negatively
charged macromolecules including collagen, fibronectin, and certain proteins found in the cell
wall or membrane of certain microorganisms. Contact with these polymers activates Factor XII,
initiating the intrinsic pathway and contributing to the formation of fibrin. Once activated,
Factor XII is converted into its active protease form of Factor XIIa, which in turn goes on to
activate Factor XI into Factor XIa and prekallikrein into plasma kallikrein by selectively
cleaving the Arg369-Ile370 found in both Factor XI and prekallikrein.

Factor XI
The next step in the intrinsic coagulation pathway, following the activation of factor XII
into factor XIIa is the activation of factor XI into factor XIa. Like factor XII, factor XI is a
zymogen that must be activated in order to perform its enzymatic functions16. In its activated
form, it is a serine protease that starts the next step of the intrinsic pathway by selectively
cleaving the arg-ala and arg-val peptide bonds found in factor IX18. Factor IX will, in turn, be
activated and be able to continue the coagulation cascade.
Factor XI, in its inactive form, is produced by the liver and circulates in the blood as a
homo-dimer17. The structure of the homo-dimer, formed by the combination of two polypeptide
6

chains, consists of four apple domains and a fifth serine protease domain. The serine protease
domain is responsible for the catalytic activity of factor XI, once activated. This activation is a
result of inactive Factor XI coming into contact with activated factor XIIa or thrombin, both of
which cleave the Arg369-Ile370 peptide bonds on both subunits of the dimer. It is thought that
this cleavage results in the partial detachment of the catalytic protease domain, giving it enough
space to properly bind to factor IX and fulfill its protease function.
There is another domain in the factor XI homo-dimer that fulfills an important function as
well. Of the four apple domains, there is one that is responsible for the binding site of a molecule
known as high molecular weight kininogen (HK). HK is the molecule responsible for carrying
factor XI and prekallikrein in the blood. HK forms a complex with inactivated factor XI by
binding to its apple domain. HK itself is not enzymatically active but is a necessary component
in the complex as factor XIIa would be unable to activate factor XI without it5.
Even though the contact activation pathway can activate Factor XI and the clotting
cascade and is often observed to be activating coagulation in lab settings3, the actual
physiological role of the contact system in vivo is hotly debated. This is due to the fact that
people who have deficiencies in the proteins that make up the system (FXII, PK, and HK) rarely
experience bleeding disorders as a result, leading many to suggest that the contact activation
pathway is a redundant system3.
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Prekallikrein
Prekallikrein, also known as Fletcher factor, is a serine protease that plays a vital role in
the contact activation pathway. In this system, prekallikrein complexes with the protein
chaperone high-molecular-weight kininogen to form the HK/PK complex. This complex can then
interact with Factor XII which cleaves the prekallikrein from HK to produce kallikrein (PKa)4.
Prekallikrein is homologous to factor XI in the coagulation cascade as it also consists of
four apple domains and a fifth, catalytic serine protease domain19. However, unlike Factor XI,
prekallikrein does not form dimers. In addition, the bond cleaved by Factor XII in the activation
of prekallikrein to kallikrein (Arg371-Ile372) is homologous to the corresponding bond cleaved
when Factor XI is activated by Factor XII20.
As was mentioned in the Factor XI section, prekallikrein and Factor XI are very closely
related with 58% identity at the amino acid level4. The Factor XI and and prekallikrein Nterminal heavy chains both consist of four apple domains. They are also both activated by the
same molecule, Factor XIIa, through cleavage of Arg-Ile bonds (Arg371-Ile372 and Arg369Ile370, respectively)4. They both also circulate as cofactors of High Molecular Weight
Kininogen, a protein chaperone vital for the proper functioning of the contact activation
pathway.

High Molecular Weight Kininogen
A key component of the contact activation pathway is the plasma protein high-molecularweight kininogen (otherwise known as HMWK or HK). High-molecular-weight kininogen acts
as a chaperone for prekallikrein (PK). HK is not enzymatically active and acts only as a cofactor
in the activation of prekallikrein5. In the contact activation pathway, HK forms a complex with
8

PK, which can be cleaved by Factor XII to produce plasma kallikrein (PKa)5. PKa, in turn, may
go on to cleave HK to produce HKa and Bradykinin.

Figure 3: The cleavage of HK by Kallikrein (PKa) to produce Bradykinin (BK) and HKa.

High molecular is also necessary for the activation of Factor XI by Factor XIIa. In the
same way that HK acts as a chaperone for the protease prekallikrein, it also acts a chaperone for
the protease Factor XI. Both Factor XI and prekallikrein circulate in the plasma in the form of
noncovalent complexes with HK. These complexes are formed from the binding of HK to the
heavy chains located in the two proteases4.

Bradykinin
Bradykinin, the product of the proteolytic cleavage of HK by PKa, is a vasoactive peptide
that plays a major role in inflammation and vascular permeability6. It is a low molecular weight
nonapeptide, which can be rapidly metabolized by certain metalloproteases such as angiotensinconverting-enzyme (ACE), neutral endopeptidase (NEP), carboxypeptidase N (CPN), and
9

aminopeptidase P6. Bradykinin can influence inflammatory processes through the activation of
endothelial cells, resulting in the promotion of vasodilation and increased vascular permeability.
It does this by binding to endothelial B1 and B2 receptors and exerting its physiological effects
(see Figure 4) These effects are what leads to the classic inflammation symptoms of redness,
heat, swelling, and pain6. We hypothesize that the vasodilation and vascular permeability
increase caused by bradykinin production, may also play a role in facilitating the spread of HIV
Tat protein.

Figure 4: Effects of
bradykinin in different
pathophysiological states.
This figure demonstrates
the various diseases and
ailments that can be
caused by the physiological
effects of BK.
Maurer M, Bader M, Bas M, Bossi F,
Cicardi M, Cugno M, Howarth P, Kaplan A,
Kojda G, Leeb‐Lundberg F, Lötvall J,
Magerl M. New topics in bradykinin
research. Allergy 2011; 66: 1397–1406.
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Objectives
The main objectives of this study is to measure the kallikrein and factor XII activity in
the transgenic mice to determine whether HIV trans-activator of transcription, (Tat) protein,
alters the structure and function of the endothelium, inducing a prothrombotic and
proinflammatory state contributing to the activation of the plasma kallikrein-kinin system (KKS)
and favoring the passage of HIV. These changes to the endothelium, possibly due to the presence
of HIV tat, facilitate leakage of infected plasma into the brain, compromising the integrity of the
blood brain barrier. It is hoped that through isolation and inhibition of tat protein, we may be
able to limit the effects of HIV spread.
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Methods and Materials
Equipment:
▪

BioTek® Synergy HTX Multi Mode Reader

▪

96-well microplate

▪

Pipette

▪

Microcentrifuge tubes for sample transfer

Reagents:

S-2302

Kallikrein – like
activity

H-D-Pro-Phe-Arg-pNA + H2O
▪

Chromogenic Substrate S-2302 (2mM)

▪

Tris Buffer, pH–7.8 (25°C)

H-D-Pro-Phe-Arg-OH + pNA

o Tris
o NaCl
o Distilled water
S-2302
In order to conduct our study on the effects of HIV Tat protein on the kallikrein-kinin
system. We decided to conduct a time course using Chromogenic Substrate S-2302 to measure
the kallikrein-like activity in the plasma. The plasma kallikrein-like activity catalyzes the
splitting of p-nitroaniline (pNA) from the substrate H-D-Pro-Phe-Arg-pNA (S-2302). This
allows us to use S-2302 to detect the activation of prekallikrein into kallikrein by Factor XII.

12

The rate at which the pNA is released is measured photometrically at 405 nm. To do this, we
prepared a solution of test plasma, Tris Buffer (pH-7.8), and Substrate S-2302.
Time Course
As this experiment required the analysis of many samples simultaneously, it was
necessary to use a 96 well microplate, where plasma solution samples were loaded into rows
based on the identity of the transgenic mouse that the plasma was harvested from. The specific
plate reader used in our experiments was the BioTek® Synergy HTX Multi Mode Reader. As the
plasma samples being used in the experiment all have different protein concentrations, it was
necessary to dilute them to the same concentration before they undergo the 1:10 dilution with
Tris Buffer. Each individual well contained 20 µL of 1:10 dilution of the sample plasma, along
with 60 µL of Tris Buffer and finally 20 µL of the selected substrate (S-2302/S-2366). This
brought the total volume of each well to 100 µL with a final substrate concentration of 400 µM.
Before the substrate can be added, it is necessary to incubate the samples in the well along with
the Tris Buffer at 37°C for 5 minutes to ensure that reagents can react in conditions resembling
the environmental conditions in the human body. After incubation, the substrate can then be
added to each well. Each sample solution was arranged into 4 rows of 4 plasma samples
harvested from different mice, each row containing three samples from the same mouse (See
Figure 5).
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A

Sample 1 +

Sample 1 +

Sample 1 +

B

Sample 2 +

Sample 2 +

Sample 2 +

C

Sample 3 -

Sample 3 -

Sample 3 -

D

Sample 4 -

Sample 4 -

Sample 4 -

Figure 5: An example of the well setup used in this experiment. Each cell on the table represents one
well on the 96-well plate. Samples are arranged in rows, with each row containing 3 identical sample
solutions.

It is necessary to be close by to the plate reader when adding the substrate to each well as
the reaction takes place extremely quickly. If one takes too long to load the plate into the reader
after addition of the substrate, the reader may only catch the tail end of the reaction and not be
able to give an accurate result on the rate of reaction. Once the plate was loaded into the reader,
the time course was allowed to run for a period of approximately 1 hour, after which the plate
was removed and the OD of the solution in the wells had been recorded. OD measurements were
taken every 5 minutes throughout the hour bring the total number of readings for each sample to
12 over the course of the hour. The rate of change in OD was used as an indication of the rate of
kallikrein substrate cleavage, as the proceeding reaction will change the color of the solution
shortly after addition of the substrate. After the data for each sample had been completely
recorded, it was compiled together and then the average rate of reaction was calculated for both
Tat + samples and Tat- samples.
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Plasma Samples (In order of Use)
Transgenic Mouse ID#

Tat

15/675

+

Stock protein concentration
(mg/mL)
2.5

20/728

-

3.2

7/672

+

3.5

6/714

-

2.5

12/739

-

3.0

16/676

+

1.7

8/673

+

1.7

14/471

-

2.5

5/713

-

4.1

17/677

+

3.3

4/712

-

3.15

18/678

+

3.16

10/737

-

4.83

3/711

-

7.04

19/727

+

3.44

2/690

+

5.19

1/689

+

4.7

19/727

+

3.44

11/738

-

4.1

10/737

-

3.44
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Inhibition Study
Following completion of the S-2302 time course, we ran an additional similar
experiment. The only difference in this experiment relative to the last time course was that after
preparing the solution in the microplate wells, 1 µL of 500 µM Soybean Trypsin Inhibitor or
Kallistop was added to measure its effect on the rate of kallikrein substrate cleavage. 1 µL of the
Tris Buffer was removed to bring the volume of buffer in each well to 59 µL so that the total
volume could remain at 100 µL to not alter the concentrations of each reagent. Other than the
addition of SBTI, nothing was changed in the methodology of this experiment, relative to the
previous one.

Data and Results
After the experiment was conducted using each plasma sample available, the relative
rates of substrate cleavage were analyzed to determine whether there was a noticeable trend in
the rate of reaction based on the presence or absence of tat protein. Upon immediate inspection
of the wells after the addition of substrate, I found that many of the wells containing Tat protein
demonstrated a very rapid color change from clear to yellow. I inferred from this that this color
change is most likely indicative of the reaction taking place. This trend did not apply to every
round of experiments, but it was observed with enough frequency to assume that the presence of
Tat was already playing a role in the rate of reaction.
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Figure 6: Experiment 1- The plasma samples were all diluted to a matching protein
concentration of 2.5 mg/mL before their 1:10 dilution. The first experiment was fairly
inconclusive as both Tat+ and Tat- samples exhibited similar rates of reaction.
Samples 728 (Tat-) and 672 (Tat+) both reacted much quicker than their counterparts
675 (Tat+) and 714 (Tat-).
*Note read numbers are in increments of five minutes, therefore read # 5 = 25
minutes in the spectrophotometer*

Figure 7: Experiment 2- This time the protein concentrations of the plasma samples,
pre- 1:10 dilution, were brought to 1.75 mg/mL. The results of the second experiment
went against what we were expecting as both of the Tat- samples reacted very
quickly while the Tat+ samples lagged behind with sample 676 (Tat+) barely reacting
at all. This could mean that there was some sort of error involved in the transfer of
reagents into the microplate or that a faulty reagent may have been used.
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Figure 8: Experiment 3- This time, protein concentrations were at 3.15 mg/mL.
Sample 678 (Tat+) rapidly reacted compared to the other samples and was able to
reach equilibrium at around 15 minutes. It was followed by sample 713 (Tat-),
however this sample was never able to reach equilibrium.

Figure 9: Experiment 4- In this experiment, protein concentrations were brought to
3.44 mg/mL. Sample 727 (Tat+) showed by far the most rapid reaction rate up until
this point, vastly exceeding the rates of the other samples in the experiment. I am not
entirely sure as to what this rapid rate can be attributed to, as all samples were at the
same protein concentration and were exposed to the same volume of substrate.
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Figure 10: Experiment 5- Protein concentrations in this experiment were the same
as the previous experiment at 3.44 mg/mL. The extremely rapid reaction rate was
observed again, however, this time it was exhibited by both Tat + samples (samples
689 and 727). These samples reached equilibrium before even 10 minutes had passed
while the Tat – samples barely reacted at all relative to the others.

Once the data had been compiled, it supported the inference that Tat protein was
influencing kallikrein activity in the plasma. On average, Tat+ plasma samples showed a relative
rate of substrate cleavage nearly twice as high as the Tat- samples. The graph below is a box and
whisker showing the relative reaction rates of all Tat+ samples and all Tat- samples through all 5
experiments. The median reaction rate of the Tat+ samples came in at around a 0.7 while the Tatsamples showed a median relative rate of around 0.25. It is also very interesting to note that the
upper quartile range of the Tat- samples fell just below the lower quartile range of the Tat+
samples.
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Figure 11: Comparing the relative rates of substrate cleavage between Tat+ and Tat- samples shows that Tat+
samples reacted much more quickly than Tat- samples. A higher rate of substrate cleavage indicates higher
levels of kallikrein activity.

It is important to note that rates of kallikrein substrate cleavage are indicative of the
amount of kallikrein activity and not necessarily the amount of kallikrein itself. While higher
kallikrein activity may be a sign of higher kallikrein levels, further investigation was required
before we could determine whether Tat protein was leading to increased production of kallikrein
or simply just facilitating the cleavage of substrate.
After investigating further, it was in fact found that the HIV-1 Tat transgenic mice
demonstrated higher levels of kallikrein present in the plasma (Figure 12). This leads us to
believe that Tat is facilitating the production of kallikrein, therefore indirectly facilitating the
production of Bradykinin as well.
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Figure 12: HIV-1
Tat transgenic mice
demonstrate higher
levels of kallikrein in
the plasma compared
to the plasma of
unaffected mice.

Now that we have observed elevated kallikrein levels in the HIV transgenic mice, we can
look for ways to inhibit that activity in order to limit the production of the byproduct, bradykinin.
As bradykinin is the molecule implicated in the compromise of endothelial selectivity associated
with HIV spread, inhibition of kallikrein production may have important medical applications for
limiting the spread of HIV throughout the body. We found that plasma kallikrein activity can in
fact be inhibited through the use of Kallistop and Soybean Trypsin Inhibitor. Plasma kallikrein
activity was reduced by Kallistop and SBTI with IC50= 1.1µM and 1.3µM. Introduction of these
inhibitors greatly reduced the measured kallikrein activity in the plasma (Figure 13).
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Figure 13: Graph demonstrating the inhibition of kallikrein activity by SBTI and Kallistop. As
concentrations of inhibitor increase, kallikrein activity, exponentially decreases. An inhibitor
concentration of just 1 µM was able to decrease kallikrein activity by approximately 90%.

Conclusion
Overall, the results of the experiment were pretty supportive of our hypothesis that HIV
Tat expression was associated with higher kallikrein activity. This correlation was found to have
a p-value of less than 0.05 signaling that this correlation is most likely not due to random chance.
We believe that this difference has to do with what was discussed earlier in this paper, that HIV
Tat protein is helping to activate the plasma kallikrein system in the plasma of transgenic mice.
By utilizing the selectivity of Chromogenic Substrate S-2302, we were able to get a visualization
of this increased kallikrein system activity. This was even observable by just looking at the wells
of many of the Tat+ samples which showed a higher tendency to quickly change from a clear
color to a yellow color within a very short time frame. As was discussed in the data section, this
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was not true for every sample as some Tat- samples showed an ability to react quickly as well,
however, not at the same frequency as Tat+ samples.
Based on the evidence compiled, I believe that it is safe to say that Tat protein plays a
major role in the facilitation of the kallikrein-kinin system. High levels of kallikrein activation in
Tat+ samples, has the derivative effect of also increasing levels of Bradykinin. Bradykinin, a
known product of kallikrein activation, is a major influence in inflammation and vascular
permeability, both of which are conducive to HIV transmission. Therefore, if one were able to
inhibit the kallikrein-kinin system, which we were able to show is possible through the use of
Kallistop and Soy Bean Trypsin Inhibitor, it could also be assumed that production of
Bradykinin would be inhibited as well, leading to a decrease in the inflammation and vascular
permeability that allows HIV virus particles to spread so efficiently. This inhibition could be a
major benefit to the integrity and structure of the endothelium in the neurovascular unit of the
blood brain barrier. As was discussed earlier, the integrity of the neurovascular unit is extremely
important in preventing the leakage of plasma into the brain parenchyma, and it is this leaky
plasma that HIV and HIV particles use to penetrate the blood brain barrier, compromising the
brain to infection in the process. That is why we believe this area deserves further research into
exactly how Bradykinin influences the endothelium and its selectivity and also that further
research should be done on possible medical applications of kallikrein-kinin inhibition and how
it could be a possible treatment for those suffering from HIV infection.
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